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Memory-like Differentiation Enhances NK Cell Responses
to Melanoma
Nancy D. Marin1, Bradley A. Krasnick2, Michelle Becker-Hapak1, Leah Conant2, Simon P. Goedegebuure2,
Melissa M. Berrien-Elliott1, Keenan J. Robbins2, Jennifer A. Foltz1, Mark Foster1, Pamela Wong1,
Celia C. Cubitt1, Jennifer Tran1, Christopher B. Wetzel2, Miriam Jacobs1, Alice Y. Zhou1,
David Russler-Germain1, Lynne Marsala1, Timothy Schappe1, Ryan C. Fields2, and Todd A. Fehniger1

ABSTRACT
Purpose: Treatment of advanced melanoma is a clinical challenge.
Natural killer (NK) cells are a promising cellular therapy for T cell–
refractory cancers, but are frequently deﬁcient or dysfunctional in
patients with melanoma. Thus, new strategies are needed to enhance
NK-cell antitumor responses. Cytokine-induced memory-like (ML)
differentiation overcomes many barriers in the NK-cell therapeutics
ﬁeld, resulting in potent cytotoxicity and enhanced cytokine production against blood cancer targets. However, the preclinical activity of
ML NK against solid tumors remains largely undeﬁned.
Experimental Design: Phenotypic and functional alterations of
blood and advanced melanoma inﬁltrating NK cells were evaluated
using mass cytometry. ML NK cells from healthy donors (HD) and
patients with advanced melanoma were evaluated for their ability to
produce IFNg and kill melanoma targets in vitro and in vivo using a
xenograft model.

Introduction
Melanoma is an aggressive cancer that remains a clinical challenge due to the high risk of recurrence and rapidly progressive
course seen in aggressive variants of the disease (1). Targeted and
immunotherapeutic approaches have revolutionized the treatment
of advanced melanoma (2). Particularly, the introduction of the
immune checkpoint blocking antibodies against CTLA-4 and PD-1
have signiﬁcantly improved the survival of patients with advanced
or metastatic melanoma (3–5). However, despite these advances,
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Results: NK cells in advanced melanoma exhibited a decreased
cytotoxic potential compared with blood NK cells. ML NK cells
differentiated from HD and patients with advanced melanoma
displayed enhanced IFNg production and cytotoxicity against
melanoma targets. This included ML differentiation enhancing
melanoma patients’ NK-cell responses against autologous targets.
The ML NK-cell response against melanoma was partially dependent on the NKG2D- and NKp46-activating receptors. Furthermore, in xenograft NSG mouse models, human ML NK cells
demonstrated superior control of melanoma, compared with conventional NK cells.
Conclusions: Blood NK cells from allogeneic HD or patients with
advanced melanoma can be differentiated into ML NK cells for use
as a novel immunotherapeutic treatment for advanced melanoma,
which warrants testing in early-phase clinical trials.

>50% of patients are refractory to checkpoint blockade (6). Furthermore, of patients who initially respond to checkpoint blockade,
approximately 50% relapse (7), highlighting the need to explore
alternative immunotherapies.
Natural killer (NK) cells are cytotoxic innate lymphoid cells (ILC)
that display potent effector responses against a wide variety of tumor
cells (8). NK cells contribute to cancer immunoediting and are
frequently deﬁcient or dysfunctional in patients with cancer (9). A
prospective clinical trial demonstrated that low NK-cell function in
blood predicted an increased risk of subsequently developing cancer
and reduced NK-cell numbers correlate with poor outcomes (10).
NK cells mediate cytotoxic functions against targets by perforin/
granzymes released from a cytotoxic synapse or via death receptor
ligands. After activation, NK cells secrete cytokines (e.g., IFNg, TNF)
and chemokines (e.g., MIP1a) that modulate the function and
trafﬁcking of other immune cells, promoting an inﬂamed tumor
microenvironment. NK-cell response to a target cell is regulated by
the balance of signals received through activating receptors (that
recognize stress-induced ligands) and inhibitory receptors [that recognize MHC class I (MHC-I)], with functionality tuned by cytokine
receptors (11, 12). Thus, NK cells recognize tumor targets in a
fundamentally different way than T cells. This feature allows NK cells
to uniquely circumvent immune evasion mechanisms involving
reduced MHC-I (13), as occurs in some tumors resistant to immune
checkpoint inhibitors. This supports the idea that NK cell–based
immunotherapy represents a promising complementary innate
immunotherapy for treating patients with advanced melanoma who
are resistant to T cell–based immunotherapies.
Prior studies of patients with melanoma have shown that NK
cells present in tumors display an altered phenotype, which may
contribute to a hypofunctional NK-cell compartment (14, 15). These
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tumor-inﬁltrating NK cells display reduced expression of activating
receptors and reduced production of cytotoxic molecules which
correlated with poor prognosis (16, 17). Therefore, therapeutic strategies that rescue NK-cell functionality resulting in enhanced antimelanoma response represent an exciting approach to investigate for
patients with advanced melanoma who are refractory to conventional
melanoma therapeutics.
Our group and others have demonstrated that human NK cells
activated brieﬂy through IL12, IL15, and IL18 receptors differentiate
into memory-like (ML) NK cells that display enhanced functionality
including antitumor responses (18–22). ML NK cells have shown to be
safe and induce clinical remissions in patients with relapsed/refractory
acute myeloid leukemia (AML; refs. 21, 23), and these cells exhibit a
variety of attributes that confers superior ability to recognize and
control tumor cells (24). ML NK cells can ignore signals from some
inhibitory receptors [inhibitory killer Ig-like receptors (iKIR)], and
exhibit increased expression of the activating receptors NKG2D,
DNAM-1, and NKp46 (21, 23), suggesting that they may be effective
in recognizing additional tumor types, such as melanoma. Indeed,
NKG2D and NKp46 were shown to trigger NK cytokine production
and degranulation in response to melanoma targets (25) and ligands
for these activating receptors are expressed by melanoma cells (26).
Because these activating receptors are signiﬁcantly upregulated in ML
NK cells compared with control NK cells (21), this might suggest that
they contribute to the control of melanoma cells by ML NK cells.
In animal models, murine IL12/15/18-induced ML NK cells were
demonstrated to have enhanced response to the melanoma cell line
B16 (22). However, the activity of human ML NK cells to control
human melanoma has not been studied. Here, using in vitro and an
in vivo preclinical studies, we tested the hypothesis that autologous and
allogeneic ML NK cells possess a superior ability to recognize and
control melanoma, compared with conventional control (c)NK cells.

Materials and Methods
Healthy donors and patient samples
Human peripheral blood mononuclear cells (PBMC) from anonymous healthy donors (HD) were obtained from leukoreduction ﬁlters
after platelet apheresis and isolated by Ficoll centrifugation. For
selected experiments (and as indicated on each ﬁgure legend), NK
cells from HD were puriﬁed using RosetteSep (STEMCELL Technol-
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Cell lines and primary tumor characterization
K562 cells (ATCC, CCL-243) were obtained in 2008, viably
cryopreserved, and thawed for use in these studies. K562 cells were
maintained for <2 months at a time in continuous culture according
to ATCC instructions. The human melanoma cell lines DM6
[MHC-I chain-related A and B (MICA/B) and UL-binding proteins
1/2/3 (ULBP 1/2/3)], DM6-RhoC-Luc, and M14 (MICA/B-neg)
were a kind gift from Beatriz Carreno (28). All lines were Mycoplasma free as tested by MycoAlert Plus Mycoplasma Detection Kit
(Lonza Rockland, Inc.). Patient-derived tumor cell lines were
generated from single-cell suspension prepared from tumor specimens, maintained in RPMI þ 10% FBS and penicillin/streptomycin,
and used within 10 passages. Further characterization of patientderived cell lines was done by staining for SOX10, Melan A, and
S100 (Supplementary Data).
NK-cell functional assays and blocking experiments
Control and ML NK cells were restimulated with K562, DM6,
M14 cells, or autologous melanoma targets for 6 hours in presence
of 1 ng/mL rhIL15. Effector/target (E:T) ratio was 5:1, unless otherwise
indicated. When indicated, control and ML NK cells were preincubated with anti-NKG2D (2.5 mg/mL; BioLegend) and anti-NKp46
(2.5 mg/mL; BioLegend) blocking antibodies 30 minutes before
coincubation with tumor targets. Cells were stained as described previously (21). Data were acquired on a Gallios ﬂow cytometer (Beckman
Coulter) and analyzed using FlowJo software (Tree Star v10.6).
NK-cell cytotoxicity against melanoma targets
Cytotoxicity of control and ML NK cells was assessed in a standard
4-hours 51Cr release assays as described previously (29). Blocking or
isotype control antibodies were added to serially diluted effectors to a
ﬁnal concentration of 2.5 mg/mL prior to the addition of labeled targets.
Percent speciﬁc lysis was calculated by: (cpm experimental  cpm
spontaneous release)/(cpm max release  cpm spontaneous release)
100. Speciﬁc killing of control and ML NK cells was also evaluated
using IncuCyte Live-cell Analysis system. A total of 10,000 GFPexpressing DM6-RhoC-Luc cells were incubated for 2 hours in a
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Natural killer (NK)-cell therapy is a rational treatment for
patients with checkpoint blockade–resistant tumors. NK cells
present in the tumor microenvironment of advanced melanoma
exhibit changes that include reduced activating receptors and
functionality. We hypothesized that the increased expression of
activating receptors, reduction in sensitivity to inhibitory killer
Ig-like receptors (KIR), and augmented cytotoxic effector molecules in memory-like (ML) NK cells will augment NK-cell antimelanoma responses. Indeed, this preclinical study demonstrates
enhanced response by ML NK cells against autologous and allogeneic melanoma targets in vitro and in vivo. Mechanistically, this
depended upon NKG2D and NKp46 recognition. As allogeneic ML
NK cells have been safely used as a cellular therapy for leukemia,
these data provide proof-of-principle to test allogeneic or autologous ML NK cellular therapy in patients with advanced melanoma.

ogies; routinely ≥95%CD56þCD3). Sixteen patients with advanced
(stage IIC–IV) melanoma were enrolled in a Protocol Review and
Monitoring Committee and Institutional Review Board–approved
protocol for tissue collection. PBMC and samples from metastatic
melanoma lesions (Met) were collected from all patients (Supplementary Table S1). Uninvolved lymph nodes (ULN; deﬁned as grossly
normal-appearing lymph nodes within a regional lymph node dissection, conﬁrmed on ﬁnal pathology microscopic analysis) were also
collected in 7 patients. Resected tumor specimens and ULN were
mechanically and enzymatically digested to prepare single-cell suspensions as described previously (27). Frozen PBMC and single-cell
suspensions from Met and ULN were thawed for mass cytometry
studies. For mass cytometry studies, HD were in the same age range of
patients with advanced melanoma (median, 58.8; range, 42–78 years).
ML NK cells were generated from PBMC as described previously (21).
Brieﬂy, 3–5  106 per mL of cells were preactivated with IL12 (10 ng/mL,
BioLegend), IL15 (50 ng/mL, Miltenyi Biotec), and IL18 (50 ng/mL,
InvivoGen) for 12 to 16 hours at 37 C/5% CO2. The same number of
cells cultured in 1 ng/mL IL15 (control NK) served as control. Cytokines
were extensively washed (three times with 50 mL PBS þ 0.5% human
albumin) to remove IL12, IL15, and IL18 and then differentiated
in vitro for 6–7 days in presence of low-dose IL15 (1 ng/mL) to
sustain cell survival.

Memory-like NK Cells and Melanoma

96-well plate and imaged prior to the addition of the NK cells at a 5:1 E:
T ratio. Real-time images were captured every 3 hours and up to
72 hours and analyzed using the Incucyte software. Data are presented
as green object counts (GFPþ DM6 melanoma cells).

Single-cell mass cytometry and analysis
PBMC from HD (N ¼ 15) and advanced melanoma (N ¼ 11)
patients as well as metastasis-inﬁltrating (Met) NK cells were assessed
by mass cytometry using a panel that encompassed 38 lineage,
maturation, costimulatory, inhibitory, as well as function-related
markers (23). Clinically uninvolved ULN were analyzed as reference
for the tissue resident NK-cell phenotype. All mass cytometry data
were collected on a Helios mass cytometer (Fluidigm) and analyzed
using Cytobank as described previously (31). An established mass
cytometry panel that included lineage and maturation markers, inhibitory and activating receptors, and function-associated molecules was
utilized (Supplementary Table S2). NK cells were identiﬁed as shown
in Supplementary Fig. S1A. For the comparative analysis of circulating
and tissue NK cells, CD127þ cells were gated out to exclude ILCs and
CD94 was included as a surrogate marker to identify the less mature
NK-cell subsets CD56bright and CD56dimCD16 cells.
Statistical analysis
The data are represented as Box and Whiskers plots showing
interquartile range with minimum and maximum values or bars that
represent mean  SEM. Differences between groups were assessed
using unpaired t test or ANOVA as appropriate. Linear mixed models
were used for repeatedly measured data, followed by Tukey post hoc
test for multiple comparisons. The data analyses were performed
using Prism v8. P values are based on two-tailed tests and P < 0.05
was considered signiﬁcant;  , P < 0.05;  , P < 0.01;  , P < 0.001;

, P < 0.0001.

Results
NK cells inﬁltrate metastatic melanoma and exhibit reduced
cytotoxic potential
Phenotypic and functional alterations have been described in blood
and tumor-inﬁltrating NK cells from patients with cancer, including
patients with advanced melanoma (14, 15, 17). To better understand
NK cells in patients with advanced melanoma, mass cytometry was
used to evaluate blood and Met NK cells. Patients with stage IIIC/IV
advanced melanoma were studied (N ¼ 11), and their clinical characteristics described in Supplementary Table S1. NK cells, monocytes,
B cells, and CD4þ and CD8þ T cells were identiﬁed in PBMC, Met and
ULN but only regulatory CD4þ T cells were found to be signiﬁcantly
higher in Met compared with PBMC (Fig. 1B; Supplementary
Fig. S1B–S1D). NK cells were found within the Met and ULN and
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Circulating NK cells from patients with advanced melanoma
exhibit an altered repertoire of activating receptors and
decreased expression of granzyme and perforin
Next, a comparative phenotypic analysis of blood NK cells from 11
patients with advanced melanoma and 15 HD was performed to deﬁne
the NK-cell multidimensional phenotype in patients with advanced
melanoma. No differences in the frequency of total NK cells were
observed between advanced melanoma and HD. However, in patients
with melanoma there were reduced CD56dimCD16 and increased
CD56dimCD16þ NK-cell frequencies (Supplementary Fig. S3A and
S3B). A multidimensional analysis showed that CD56bright NK cells
from patients with advanced melanoma exhibited decreased expression
of the activating receptors NKp44 and DNAM-1, with no other major
changes (Supplementary Fig. S3C and S3F). Similarly, CD56dimCD16þ
NK cells also exhibited reduced DNAM1 as well as GzmB and perforin
expression (Supplementary Fig. S3D and S3G) while modest changes in
the activating receptors NKG2D and NKp46 expression were found in
CD56dimCD16 NK cells from advanced melanoma compared with
HD (Supplementary Fig. S3E and S3H). These data, in concert with
prior studies, suggest that blood NK cells from patients with advanced
melanoma have reduced expression of activating receptors and cytotoxic potential. This altered functionality was more pronounced in
advanced melanoma–resident NK cells suggesting that approaches to
enhance anti-melanoma activity of NK cells will be required for an
effective autologous response.
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Adoptive transfer of control and ML NK cells into NSG mice
NOD-scid IL2Rg null (NSG) mice (6–10 weeks old; Jackson Laboratories) were irradiated with 250 cGy and injected with 1  105
DM6-RhoC-Luc (intraperitoneal) at day 0. Five million control or
preactivated NK cells generated as described in Fig. 3A (21) were
injected intraperitoneally in tumor-bearing mice at day 1. Mice were
conﬁrmed for the presence of tumor by bioluminescent imaging (BLI)
before intraperitoneal NK-cell injection and imaged weekly for the
duration of the experiment. rhIL2 (50,000 IU) was administered
intraperitoneally every other day to support transferred cells. BLI was
performed on an amiHT optical imaging system (1–60 seconds
exposure, bin8, FOV12 cm, open ﬁlter) as described previously (30).

were predominantly CD56bright NK cells, as previously reported for
secondary lymphoid tissues (32). CD56dimCD16þ NK cells were more
frequent in blood (Fig. 1C) although a small percentage was also
detected in both Met and ULN. NK cells in tissue expressed high levels
of CD69 and decreased levels of CD62L, consistent with a tissue
(lymph node) resident phenotype (Supplementary Fig. S2). Frequencies of both total NK cells and NK-cell subsets were not different
between Met and ULN (Fig. 1C). Analysis of maturation, chemokine
receptors, and function-related markers showed no differences in the
phenotype of CD56bright NK cells from the three tissue sources
(Fig. 1D and G). In contrast, CD56dimCD16þ NK cells inﬁltrating
tissue exhibited diminished cytotoxic potential indicated by a reduced
expression of granzyme B (GzmB) and perforin (Fig. 1E and H). In
addition to the conventional CD56bright and CD56dimCD16þ NK-cell
subsets, we also detected the aberrant subset of CD56dimCD16 NK
cells that have been previously reported in patients with chronic viral
infection and cancer (33, 34). CD56dimCD16 NK cells inﬁltrating
tumor tissue also exhibited reduced expression of GzmB and perforin
compared with paired PBMC (Fig. 1F and I). CD56dimCD16þ NK cells
from ULN expressed higher levels of NKG2A suggesting a less
differentiated phenotype compared with their counterpart in blood.
The high CXCR1 and low CXCR3 expression that mark mature
CD56dimCD16þ NK cells in blood (35, 36) also contrasted with the
phenotype of tissue-resident NK cells, which expressed low CXCR1 and
high CXCR3 (Fig. 1F). These data are consistent with previous ﬁndings
showing that immature CD56brightCD16 NK cells are a predominant
population in advanced melanoma lymph nodes (34). Thus, NK cells
inﬁltrate advanced melanoma environments and exhibit a reduced
cytotoxic potential with decreased expression of GzmB and perforin,
a defect that could be addressed by adoptive NK-cell therapies.

ML NK cells from HD PBMC exhibit enhanced ability to control
melanoma compared with conventional NK cells
ML NK cells exhibit potent cytotoxic functions and enhanced
ability to produce cytokines upon in vitro or in vivo restimulation
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with tumor targets (21, 22, 37). However, activity of human ML NK
responses against solid tumors remains largely undeﬁned. To
address this, we evaluated the ability of ML NK cells from HD to
respond and kill melanoma cells. ML NK cells from HD were
generated following IL12, IL15, and IL18 receptor activation using
PBMC as described previously (Fig. 2A), allowed to differentiate,
and then restimulated with the human melanoma cell lines DM6
and M14. These were compared with conventional (cNK, control)

4862 Clin Cancer Res; 27(17) September 1, 2021

NK cells maintained in low-dose IL15 for survival. Despite the high
expression of human NKG2D ligands MICA/B and ULBP1/2/3 (29)
in DM6 cells, only a modest increase in IFNg production and
CD107a expression (as a surrogate for degranulation) was evident
in control NK cells (Fig. 2B–E). No signiﬁcant induction of IFNg
was observed in control NK cells upon stimulation with M14 cells,
which have reduced MICA/B expression. In contrast, ML NK cells
from the same HD had signiﬁcantly increased IFNg, TNF, and
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Figure 1.
NK cells inﬁltrating metastatic melanoma are mostly immature CD56bright and less frequently mature CD56dim NK cells that exhibit reduced cytotoxic molecules.
A, Representative example of a viSNE map showing the distribution of main immune subsets in PBMC, metastatic (Met), and ULN from a patient with advanced
melanoma. B, Percent of NK cells (CD56þCD3) within CD45þ cells. C, Three NK-cell subsets were identiﬁed based on CD56 and CD16 expression: CD56bright,
CD56dimCD16þ, and CD56dimCD16 and their frequency within total NK cells is shown. D, NK cells were analyzed for the expression of NK cell–associated markers
using mass cytometry (see Supplementary Table S2). D–F, Maturation markers (NKG2A, CD57), chemokine receptors (CXCR1, CXCR3) and function-related
molecules (GRZB, Perf) in CD56bright, CD56dimCD16þ and CD56dimCD16 assessed by mass cytometry. G–I, Median of GzmB and perforin expression in NK cells from
the three tissue sources. Box and Whiskers plots show interquartile range with min and max values. Two-way ANOVA test, mixed effects model with Tukey post hoc
test.  , P < 0.05;   , P < 0.01;    , P < 0.001;    , P < 0.0001. n ¼ 11 PBMC, n ¼ 11 Met, n ¼ 7 ULN.

Memory-like NK Cells and Melanoma

CD107a expression after restimulation with DM6 and M14 melanoma cells (Fig. 2B–E). Superior cytokine response and degranulation of ML NK cells was also signiﬁcant when puriﬁed NK cells
were used instead of PBMC (Supplementary Fig. S4A–S4C). Consistent with increased degranulation, ML NK cells from HD also
exhibited signiﬁcantly increased and sustained cytotoxicity, thereby
eliminating melanoma target cells even at low E:T ratios (Fig. 2E
and F). These results support a signiﬁcantly enhanced ability of ML
NK cells to control melanoma targets in vitro.

AACRJournals.org
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Figure 2.
ML NK cells from normal donors exhibit
enhanced ability to control melanoma
compared with conventional NK cells. A,
PBMC-derived NK cells from HD were
activated with IL12/IL15/IL18 (or IL15 alone
as control) for 16–18 hours (1). Activated
NK cells were differentiated into ML NK
cells in vitro during 7 days in presence of
low-dose IL15 (2). Upon a second stimulation (3), ML NK cells exhibited enhanced
responses against tumor target and cytokines, compared with control or conventional NK cells. B, Representative ﬂow
cytometry and gating strategy to evaluate
cytokine secretion and degranulation
(CD107aþ cells) of control and ML NK cells
stimulated with melanoma cell lines (DM6,
M14) and K562 cells. Numbers indicate
percentage of positive cells. Summary
data of IFNg (C), TNF (D), and degranulation of control (blue) and ML (green) NK
cells (E) restimulated 6 hours in vitro with
DM6, M14, and K562 cells. Cells lines were
used at a 10:1 E:T ratio. ML NK cell exhibited superior killing ability against DM6
compared with control NK cells in a
standard 4-hours 51Cr release assay (F)
and a 72-hour Incucyte assay (G). Puriﬁed
NK cells were used for the cytotoxic
assays. Bars represent mean  SEM. Twoway ANOVA test.  , P < 0.05;   , P < 0.01;

, P < 0.001;     , P < 0.0001. n ¼ 3 in
C–E, n ¼ 9 in F. G shows a representative
experiment out of three independent
experiments.

ML NK cells differentiated from patients with advanced
melanoma exhibit enhanced ability to control autologous tumor
We next asked whether ML NK cells could be generated from patients
with advanced melanoma and whether they are able to control autologous melanoma targets. PBMC from patients with advanced melanoma (n ¼ 7; Supplementary Table S1) were stimulated as described
in Fig. 3A and their NK cells differentiated into ML NK cells (Fig. 3A).
Autologous primary melanoma cells generated from metastatic lesions
were used as targets in functional assays. For all patients, IHC staining of
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S100, MelanA, and SOX10 conﬁrmed these cell lines to be metastatic
melanoma (Supplementary Fig. S5). When restimulated with autologous melanoma targets, ML NK cells exhibited a signiﬁcantly increased
IFNg production compared with control NK cells (Fig. 3B and C). In
contrast to ML NK cells from HD (Fig. 2), autologous ML NK cells from
patients with advanced melanoma also exhibited increased baseline
IFNg production. ML NK cells from patients with advanced melanoma
also exhibited a signiﬁcant increase in speciﬁc killing of autologous
melanoma cells compared with control NK cells, even at low E:T ratios
(Fig. 3D). As expected, there were no signiﬁcant differences in CD107a
in ML NK cells versus control NK cells when cells were restimulated
with autologous melanoma targets or K562 cells (Supplementary
Fig. S6A and S6B). These data suggest that the ML NK cells can be
generated from patients with advanced melanoma and that the ML
differentiation program restores IFNg production and cytotoxicity
against autologous advanced melanoma targets.
Enhanced response of ML NK cells from patients with advanced
melanoma against advanced melanoma targets are NKG2D and
NKp46 dependent
NKG2D and NKp46 mediate NK responses against melanoma
targets (25). Because these activating receptors are signiﬁcantly

4864 Clin Cancer Res; 27(17) September 1, 2021

upregulated in ML NK cells compared with control NK cells (21),
we next evaluate their contribution to patient-derived ML NK-cell
recognition of melanoma targets. For this, NKG2D and NKp46
were blocked and changes in NK-cell responses against autologous
tumor were assessed. All primary melanoma cells consistently
expressed the stress-induced NKG2D ligand MICA/B (Fig. 4A).
IFNg production from both patient-derived control NK and ML NK
cells were signiﬁcantly diminished in presence of both NKG2D and
NKp46 blockade (Fig. 4B and C). These differences were not
associated with reduced cell viability of control and ML NK cells
(Supplementary Fig. S6C). Furthermore, degranulation but not
TNF production was markedly reduced in both control NK cells
and ML NK cells (Supplementary Fig. S6D–S6E). Consistent with
this, the killing of autologous melanoma targets by control NK cells
and ML NK cells was also signiﬁcantly impaired following blockade
of these activating receptors (Fig. 4D). Similar reduction in cytokine response, degranulation, and killing was found after stimulation of HD-puriﬁed NK cells with DM6, suggesting a speciﬁc effect
on NK cells (Supplementary Fig. S6F–S6I). Importantly, reduced
NK-cell functionality was signiﬁcantly affected by simultaneous
blockade of NKG2D and NKp46 rather than single blockade
(Supplementary Fig. S6J and S6K). Together, these results
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Figure 3.
Memory-like NK cells from patients with
advanced melanoma exhibit enhanced ability to control autologous tumor. A, PBMC
containing patient NK cells were preactivated as indicated in Fig. 2A. Melanoma cell
lines generated from metastatic tissue were
used as target cells for the functional assays.
B, Representative ﬂow cytometry plots of
control and ML NK cells from a patient with
advanced melanoma stimulated with autologous tumor. Numbers indicate percentage
of positive cells. ML NK cells (green) from
patients with melanoma patients display
superior ability to produce IFNg upon stimulation with autologous tumor (5:1 E:T ratio)
compared with control NK cells (blue; C).
D, ML NK cells from patients with advanced
melanoma exhibit superior ability to kill
autologous melanoma targets compared
with control NK cells at different E:T ratios.
Killing was evaluated in a standard 4-hours
51
Cr release assay. Bars represent mean 
SEM from all patients. Two-way ANOVA
with Tukey post hoc analysis.  , P < 0.05;

, P < 0.01;   , P < 0.001;    , P < 0.0001.
n ¼ 7.
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demonstrate the critical role of NKG2D and NKp46 in the enhanced
response of ML NK cells against autologous melanoma targets.
ML NK cells control melanoma targets in an NSG xenograft
model
Next, human ML NK cells were evaluated for their ability to control
melanoma targets in vivo using a human xenograft model into
immunodeﬁcient NSG mice. NSG mice were injected with 1  105
DM6-RhoC-Luc cells (intraperitoneal), and 1 day later mice received a
single injection of 5  106 control NK cells or ML NK cells (intraperitoneal). Because NSG mice lack a homeostatic IL2/15R ligand
required to support NK-cell survival and expansion, IL2 (50,000 IU/
mouse) was injected every other day (intraperitoneally) to support
transferred human NK cells (21) and the melanoma burden was
monitored by BLI weekly (Fig. 5A). Mice receiving control NK cells
were able to signiﬁcantly control melanoma tumor burden compared
with untreated mice, although the tumor advanced over time. In
contrast, mice adoptively transferred with a single dose of ML NK
cells (from the same donors) exhibited a signiﬁcantly superior ability to
control melanoma cells in vivo, with the tumor burden controlled over
the duration of the experiment (Fig. 5B and C). These data indicate
that a single injection of ML NK cells provided enhanced control or
melanoma targets in vivo, compared with control NK cells.

Discussion
Here, we demonstrated that IL12, IL15, and IL18 receptor induced
ML NK cells from HD and patients with advanced melanoma exhibit
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an enhanced ability to attack melanoma targets. ML differentiation of
patients’ blood NK cells resulted in enhanced ability to produce IFNg
and kill autologous melanoma targets. We also identiﬁed NKG2D and
NKp46 as a recognition mechanism underlying the enhanced functionality of ML NK cells against melanoma. Using mass cytometry and
multidimensional analysis, we found that patient NK cells inﬁltrating
tumors exhibited a dysfunctional phenotype with reduced expression
of cytotoxic molecules and altered expression of chemokine receptors
compared with patient-matched blood NK cells. Furthermore, circulating NK cells from patients with advanced melanoma exhibited
reduced expression of activating receptors, GzmB, and perforin when
compared with HD blood NK cells. Thus, the ML differentiation of NK
cells from dysfunctional patients with advanced melanoma or HD
represents new approaches to enhance NK-cell anti-melanoma attack
and warrants further investigation as a cellular therapy.
Immune checkpoint blockade (ICB) therapy targeting PD-1 and
CTLA-4 as single or combined therapy has revolutionized the treatment of patients with several cancer types including melanoma (38, 39).
Blocking these inhibitory receptors enhances T cell–mediated antitumor immune responses, leading to improved clinical responses and
survival of patients with advanced melanoma (38, 39). However,
despite their successes, immune- and drug-related adverse effects are
common and affect >50% of the patients receiving the combination
therapy (38). In addition, >50% of the patients fail to ever respond and
approximately 50% of those who initially respond, become resistant
and eventually develop progressive disease (5, 7, 40). In addition, for
those with BRAF-mutant melanoma tumors, targeted therapy alone
has led to survival improvements (41); however, this is not curative.
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Figure 4.
Enhanced ML responses are partially dependent on NKG2D and NKp46. A, Expression of the NKG2D ligand MICA/B in primary tumors. Patient-derived control and ML
NK cells were stimulated for 6 hours with autologous tumor with or without aNKG2D (2.5 mg/mL) plus aNKp46 (2.5 mg/mL) blocking antibodies and the frequency of
IFNg was evaluated by ﬂow cytometry. Representative ﬂow cytometry dot plots (B) and summary data (C) showing reduction in IFNg production by control
and ML NK cells after NKG2D and NKp46 blockade. D, Patient-derived control and ML NK cells were stimulated in the presence of autologous tumor with or
without blocking antibodies and speciﬁc killing was measured by 51Cr release assay. Bars represent mean  SEM from all patients. Two-way ANOVA and paired t test

, P < 0.05;   , P < 0.01;    , P < 0.001;    , P < 0.0001. n ¼ 7.
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Tumor intrinsic and extrinsic mechanisms are associated with resistance to ICB including downregulation of MHC-I antigen presentation
pathways by tumor cells to evade a cytotoxic T-cell antigen-speciﬁc
immune response (40, 42). NK cells have emerged as a promising
therapy for treating patients with cancer as they are safe and exert
potent antitumor responses (24, 43). Their ability to recognize tumor
cells in an antigen-independent manner allows NK cells to circumvent
immune evasion mechanisms involving reduced MHC-I expression (40, 42). Thus, NK cells become a suitable therapy for treating
tumors that have failed ICB, targeted, and T cell–based therapies.
The recently discovered memory properties of innate immune cells,
also referred to as trained immunity, have changed the paradigm of
enhanced recall responses as an exclusive feature of adaptive T and B
cells. NK cells that remember their prior experiences have been
described in response to haptens, viral infections, and cytokine stimulation (18, 19, 44). We and others have shown that a short-term
stimulation through IL12, IL15, and IL18 receptors induce NK cells
with an enhanced ability to produce IFNg, TNF, and MIP1a in
response to cytokines, activating receptors triggering or restimulation
with tumor targets (19, 21, 22). Cytokine-induced ML NK-cell therapy
has been tested in patients with leukemia and was both safe and
effective, inducing complete remission in 47% of patients with
relapsed/refractory AML (23). The ﬁrst evidence demonstrating the
ability of ML NK cells to reject solid tumors was reported in syngeneic
mouse models by the Cerwenka laboratory (22, 37). In those studies,
IL12/15/18-activated NK cells exhibited a stable and persistent
enhanced ability to control B16 melanoma cells in vivo, in a mech-
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anism dependent on IL2 produced by CD4þ T cells. More recently,
Uppendahl and colleagues (45) demonstrated enhanced functionality
and cytotoxicity of peritoneal NK cells against ovarian cancer cells after
activation with IL12, IL15, and IL18. Our data advance these ﬁndings
and show that both allogenic and autologous blood ML NK cells can
effectively control human melanoma cells. The ML differentiation
program also imprints NK cells with speciﬁc phenotypic and molecular changes that includes upregulation of activating receptors
(NKG2D, NKp46, DNAM1), the ability to rescue unlicensed NK cells
and respond to both KIR ligand matched and mismatched NK
cells (20, 21), and to ignore inhibitory KIR signals (21). These
attributes provide the rationale for the use of autologous or allogeneic
ML NK cells as cellular therapy in melanoma. Inﬁltration of NK cells in
melanoma correlates with improved prognosis and survival (10, 17),
and multiple phenotypic and functional alterations have been
described in blood and melanoma-inﬁltrating NK cells (14, 15, 17).
Consistent with prior reports, we observed reduced NKp44 and
DNAM1 expression in blood NK cells from patients with advanced
melanoma (14, 25), partially accounting for the reduced antimelanoma response. In addition, the expression of ligands for these
activating receptors in melanoma cells also suggests a key role for these
ligand-receptor interactions in the tumor recognition and induction of
NK antitumor properties against melanoma targets (46). NKG2D and
NKp46 are also expressed at low levels by NK cells from patients with
melanoma (25) and they are required for an efﬁcient tumor recognition and induction of antitumor responses against melanoma targets (46). Consistent with this, we demonstrated that the enhanced
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Figure 5.
Human ML NK cells effectively control melanoma targets in a xenograft model in NSG mice. A, NSG mice were injected with 1  105 (i.p.) DM6 melanoma cells
expressing RhoC/Luc 1 day before NK-cell injection. At day 1, tumor-bearing mice were injected with 5  106 control or ML NK cells (intraperitoneal) and the tumor
burden was assessed using BLI every week (B). BLI images in B are representative from one of three independent experiments. C, Summary data indicate that
allogenic ML NK cells control melanoma targets in vivo better than control NK cells. Three to seven mice per group from three independent experiments. C, Data from
all mice from the three experiments (untreated ¼ 11 mice, control NK cells ¼ 16 mice, and ML NK cells ¼ 15 mice). Two-way ANOVA - mixed-effect model with Tukey
post-test.  , P < 0.05;    , P < 0.001.
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mouse model and melanoma cell line in an immunocompetent
setting, Ni and colleagues initially reported that radiotherapy was an
important, potentially by providing a lymphodeplete niche for
expanding ML NK cells (22). Studies by the Cooper laboratory (50)
have also explored this in vivo in murine ML NK-cell responses in
the setting of homeostatic proliferation, and radiotherapy was not
required in this lymphodeplete setting. We have performed adoptive transfer of human NK cells into irradiated and nonirradiated
NSG mice without major differences in their ability to persist.
Furthermore, our clinical studies in leukemia did not include
radiotherapy, with robust ML NK-cell responses evident in vivo
in patients. In this setting, the ﬂu/cy lymphodepleting chemotherapy likely takes the place of radiotherapy used in the initial murine
syngeneic ML NK-cell responses to B16 melanoma and RMAS
lymphoma. Finally, while the evaluation of primary melanoma
patient ML NK cells in vivo in NSG mice would be interesting,
this is technically very challenging requiring large volume blood
collection or leukapheresis, which was not performed during this
preclinical study.
In summary, ML NK cells exhibit an enhanced ability to control
melanoma targets in vivo and in vitro in preclinical experiments.
Importantly, we demonstrated that the ML differentiation programming rescues dysfunctional NK cells in patients with advanced melanoma and that patient-derived ML NK cells efﬁciently control
autologous tumor. This provides a rationale for the use of ML NK
cells as an alternative immunotherapy to treat patients with advanced
melanoma resistant to standard therapies, supporting advancement of
ﬁrst-in-human clinical trials in melanoma.
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functionality of ML NK cells against melanoma is partially dependent
on the recognition of melanoma cells by these activating receptors.
Even though we did not test the expression of NKp46 ligands on
patient-derived tumor cells, our results using DM6 cells suggest that
blockade NKG2D is relatively more important than NKp46 to inhibit
anti-melanoma responses of NK cells. In addition, the reduced
response of ML NK cells against M14 cells which have reduced
expression of NKG2D ligands (MICA/B, ULBP1/3; ref. 29) support
the concept, but also indicate additional activating receptor and ligand
interactions may contribute. The enhanced expression of these activating NK receptors on ML NK cells supports the premise that ML
NK-cell program can rescue the hypofunctional phenotype of poorresponding NK cells from patients with advanced melanoma.
Using mass cytometry, we also identiﬁed alterations in NK cells
within the tumor microenvironment. Besides CD56bright and mature
CD56dim NK-cell subsets commonly identiﬁed in blood, CD56dim NK
cells also inﬁltrated metastatic lesions (34, 47), suggesting recirculation
of mature NK cells from the periphery as part of their normal immunosurveillance. We also identiﬁed the atypical CD56dimCD16 NK-cell
population inﬁltrating melanomas. This subset was described to contain
maturing and target cell–activated NK cells (48), and was identiﬁed as an
NK-cell subset in melanoma tissue (34, 48). The relationship between
CD56dimCD16 NK cells to the better characterized CD56brightCD16
and CD56dimCD16þ remains unclear, but because this population is
increased in the setting of disease or chronic activation, may represent
chronically activated/exhausted NK cells. Future studies should focus on
the cellular and molecular differences of this cell type across different
disease states, to HD. When comparing the three tissue sources, the
signiﬁcant differences associated with the location in tissue (whether
Met or ULN), compared with PBMC, likely accounted for by the distinct
NK cells that are present in secondary lymphoid tissue, with
CD56brightCD16 NK cells being predominant in the lymph nodes (32).
There were differences based on tissue location of chemokine receptors
in CD56dimCD16þ from PBMC having higher CXCR1 and lower
CXCR3, compared with the lymph node samples. This was not evident
in the CD56brightCD16 subset, which may indicate distinct homing
receptor use or development within the tissue.
Tumor-inﬁltrating NK cells have been reported to have reduced
expression of cytotoxic molecules (49). Our data support those ﬁndings and demonstrated the most severe defect in the cytotoxic subsets
CD56dimCD16þ and CD56dimCD16 NK cells. Furthermore, considering the immunosuppressive nature of the tumor microenvironment,
we expected to see greater differences between Met and ULN, with
reduced GzmB and perforin in the Met situation. In contrast, this also
appeared to be associated based on tissue location, with reduced GzmB
and perforin in both Met and ULN compared with PBMC, as reported
previously (17). However, both Met and ULN are within the patient
with advanced melanoma and in the same lymphatic drainage, and
thus may represent a general feature of NK alteration in patients with
melanoma. This hypofunctional phenotype correlated with the poor
responses of conventional NK cells against melanoma targets observed
in this study.
Preclinical data presented in this study and by others, and data
from our current clinical trials, have demonstrated superior functionality and persistence of ML NK cells in vivo, partially dependent
on the homeostatic cytokines IL2 or IL15 (22, 23, 37). Because of the
lack of a homeostatic IL2/15R ligand in NSG mice, rhIL2 was
injected to support transferred human NK cells in NSG mice as
initially demonstrated by the Cerwenka Laboratory (22). In addition, differences in the requirement for radiotherapy in this and
other studies are likely model dependent. Utilizing a syngeneic
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